Q-omics provides the consensus-scored LINC01381 profile across patient tissues and cancer cell-line models. LINC01381 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LINC01381 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, LINC01381 RNA expression shows 6,349 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, BRCA, and STAD as cancer lineages where LINC01381 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01381 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01381 survival associations across molecular data types. LINC01381 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01381 RNA expression–survival associations across cancer types. High LINC01381 expression shows unfavorable associations in KICH, STAD and MESO, but favorable associations in OV, KIRP and PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for LINC01381 RNA expression.
This table summarizes LINC01381 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01381. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01381 shows lower tumor expression in BRCA, KIRC, KICH, THCA and ESCA and higher tumor expression in LUSC. The BRCA box plot shows higher LINC01381 RNA expression in normal versus tumor tissue (log2 FC = −0.131, t-test p < 0.001).
This table shows molecular features associated with LINC01381 in patient tissues and cancer cell lines. In patient samples, LINC01381 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
